These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 19348934)

  • 1. The influence of hepatic damage on serum soluble Fas ligand levels of patients with drug rashes.
    Tohyama M; Shirakata Y; Sayama K; Hashimoto K
    J Allergy Clin Immunol; 2009 Apr; 123(4):971-2; author reply 972. PubMed ID: 19348934
    [No Abstract]   [Full Text] [Related]  

  • 2. Increased soluble Fas ligand levels in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis preceding skin detachment.
    Murata J; Abe R; Shimizu H
    J Allergy Clin Immunol; 2008 Nov; 122(5):992-1000. PubMed ID: 18692887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toxic epidermal necrolysis and Stevens-Johnson syndrome: soluble Fas ligand involvement in the pathomechanisms of these diseases.
    Abe R
    J Dermatol Sci; 2008 Dec; 52(3):151-9. PubMed ID: 18657400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum levels of the Th1 promoter IL-12 and the Th2 chemokine TARC are elevated in erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis and correlate with soluble Fas ligand expression. An immunoenzymatic study from the Italian Group of Immunopathology.
    Quaglino P; Caproni M; Antiga E; Del Bianco E; Osella-Abate S; Savoia P; Frezzolini A; Schena D; Marzano A; Volpi W; De Simone C; Parodi A; Fabbri P; Bernengo MG;
    Dermatology; 2007; 214(4):296-304. PubMed ID: 17460400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic role of soluble fas ligand secretion by peripheral blood mononuclear cells from patients with previous drug-induced blistering disease: a pilot study.
    Lan CC; Wu CS; Tsai PC; Chen GS
    Acta Derm Venereol; 2006; 86(3):215-8. PubMed ID: 16710577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Fas Ligand gene polymorphism with Stevens-Johnson syndrome.
    Ueta M; Sotozono C; Inatomi T; Kojima K; Hamuro J; Kinoshita S
    Br J Ophthalmol; 2008 Jul; 92(7):989-91. PubMed ID: 18577653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Soluble FAS ligand: a discriminating feature between drug-induced skin eruptions and viral exanthemas.
    Stur K; Karlhofer FM; Stingl G
    J Invest Dermatol; 2007 Apr; 127(4):802-7. PubMed ID: 17139262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Borchers AT; Lee JL; Naguwa SM; Cheema GS; Gershwin ME
    Autoimmun Rev; 2008 Sep; 7(8):598-605. PubMed ID: 18603022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Soluble Fas ligand: is it a critical mediator of toxic epidermal necrolysis and Stevens-Johnson syndrome?
    Murata J; Abe R
    J Invest Dermatol; 2007 Apr; 127(4):744-5. PubMed ID: 17363955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis.
    Levi N; Bastuji-Garin S; Mockenhaupt M; Roujeau JC; Flahault A; Kelly JP; Martin E; Kaufman DW; Maison P
    Pediatrics; 2009 Feb; 123(2):e297-304. PubMed ID: 19153164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A marked increase in serum soluble Fas ligand in drug-induced hypersensitivity syndrome.
    Tohyama M; Shirakata Y; Sayama K; Hashimoto K
    Br J Dermatol; 2008 Sep; 159(4):981-4. PubMed ID: 18637896
    [No Abstract]   [Full Text] [Related]  

  • 12. Drug eruptions in children.
    Shin HT; Chang MW
    Curr Probl Pediatr; 2001 Aug; 31(7):207-34. PubMed ID: 11500668
    [No Abstract]   [Full Text] [Related]  

  • 13. [Disseminated intravascular coagulation in skin diseases].
    Płatek-Twardoch C
    Przegl Dermatol; 1984; 71(6):609-14. PubMed ID: 6399129
    [No Abstract]   [Full Text] [Related]  

  • 14. Serum interleukin-13 levels are increased in patients with Stevens-Johnson syndrome/ toxic epidermal necrolysis but not in those with erythema multiforme.
    Quaglino P; Caproni M; Osella-Abate S; Torchia D; Comessatti A; Del Bianco E; Antiga E; Frezzolini A; Schena D; Marzano A; De Simone C; Parodi A; Fabbri P; Bernengo MG
    Br J Dermatol; 2008 Jan; 158(1):184-6. PubMed ID: 17941938
    [No Abstract]   [Full Text] [Related]  

  • 15. Practical guidelines for the management of toxic epidermal necrolysis and Stevens-Johnson syndrome.
    Fromowitz JS; Ramos-Caro FA; Flowers FP;
    Int J Dermatol; 2007 Oct; 46(10):1092-4. PubMed ID: 17910723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An update on Stevens-Johnson syndrome and toxic epidermal necrolysis in children.
    Koh MJ; Tay YK
    Curr Opin Pediatr; 2009 Aug; 21(4):505-10. PubMed ID: 19474732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Lee HY; Pang SM; Thamotharampillai T
    J Am Acad Dermatol; 2008 Aug; 59(2):352-3. PubMed ID: 18638633
    [No Abstract]   [Full Text] [Related]  

  • 18. European Dermatology Forum: skin diseases in Europe. Skin diseases with a high public health impact: toxic epidermal necrolysis and Stevens-Johnson syndrome.
    Fritsch P
    Eur J Dermatol; 2008; 18(2):216-7. PubMed ID: 18424404
    [No Abstract]   [Full Text] [Related]  

  • 19. Erythema multiforme/Stevens-Johnson syndrome/toxic epidermal necrolysis in lenalidomide-treated patients.
    Castaneda CP; Brandenburg NA; Bwire R; Burton GH; Zeldis JB
    J Clin Oncol; 2009 Jan; 27(1):156-7. PubMed ID: 19047275
    [No Abstract]   [Full Text] [Related]  

  • 20. Serum soluble Fas ligand levels and peripheral blood lymphocyte subsets in patients with drug-induced maculopapular rashes, dress, and viral exanthemas.
    Yazicioglu M; Gokmirza Ozdemir P; Turgut B; Sut N
    Allergol Immunopathol (Madr); 2020; 48(4):339-347. PubMed ID: 31375337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.